Records 1-6 (of 6 Records) |
Query Trace: IGHV3-66[original query] |
---|
Stereotypic neutralizing V antibodies against SARS-CoV-2 spike protein receptor binding domain in patients with COVID-19 and healthy individuals. Kim Sang Il, et al. Science translational medicine 2021 0 0. (578) |
Immunodominant antibody germlines in COVID-19. Andreano Emanuele, et al. The Journal of experimental medicine 2021 5 0. (5) |
Paired heavy and light chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses. Banach Bailey B, et al. bioRxiv : the preprint server for biology 2021 1 0. |
Neutralizing antibodies targeting SARS-CoV-2 spike protein. Xiaojie Shi, et al. Stem cell research 2020 0 0. 102125 |
Paired Heavy and Light Chain Signatures Contribute to Potent SARS-CoV-2 Neutralization in Public Antibody Responses Banach, Bailey B et al. SSRN December 23 2020 |
Stereotypic Neutralizing VH Clonotypes Against SARS-CoV-2 RBD in COVID-19 Patients and the Healthy Population Kim, Sang Il et al. bioRxiv June 29 2020 |
Disclaimer: Articles listed in the Public Health
Knowledge Base are selected by the CDC Office of Public Health
Genomics to provide current awareness of the literature and news.
Inclusion in the update does not necessarily represent the views of
the Centers for Disease Control and Prevention nor does it imply
endorsement of the article's methods or findings. CDC and DHHS assume
no responsibility for the factual accuracy of the items presented. The
selection, omission, or content of items does not imply any
endorsement or other position taken by CDC or DHHS. Opinion, findings
and conclusions expressed by the original authors of items included in
the update, or persons quoted therein, are strictly their own and are
in no way meant to represent the opinion or views of CDC or DHHS.
References to publications, news sources, and non-CDC Websites are
provided solely for informational purposes and do not imply
endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 18, 2024
- Content source: